110 related articles for article (PubMed ID: 22342570)
21. Cetuximab approved by FDA for treatment of head and neck squamous cell cancer.
Cancer Biol Ther; 2006 Apr; 5(4):340-2. PubMed ID: 16808060
[No Abstract] [Full Text] [Related]
22. Pre-medications for cetuximab induced infusion reactions - commentary.
McKibbin T; Donald Harvey R; Saba NF
Oral Oncol; 2014 Dec; 50(12):e71. PubMed ID: 25223595
[No Abstract] [Full Text] [Related]
23. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis.
Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT
Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848
[TBL] [Abstract][Full Text] [Related]
24. Response to: 'Pre-medications for cetuximab induced infusion reactions - commentary'.
Adkins D; Ley J
Oral Oncol; 2014 Dec; 50(12):e72. PubMed ID: 25282254
[No Abstract] [Full Text] [Related]
25. The efficacy of combined treatment with cetuximab (erbitux) and radiation therapy in patients with head and neck cancer.
Koukourakis G; Kouloulias V; Koukourakis M; Kouvaris J; Zacharias G; Gouliamos A
J BUON; 2009; 14(1):19-25. PubMed ID: 19373942
[TBL] [Abstract][Full Text] [Related]
26. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes.
Giro C; Berger B; Bölke E; Ciernik IF; Duprez F; Locati L; Maillard S; Ozsahin M; Pfeffer R; Robertson AG; Langendijk JA; Budach W
Radiother Oncol; 2009 Feb; 90(2):166-71. PubMed ID: 18977050
[TBL] [Abstract][Full Text] [Related]
27. Grading system and management guidelines for dermatitis induced by head and neck radiotherapy plus cetuximab: clinical validation required.
Langendijk JA; Oosting SF
Ann Oncol; 2011 Oct; 22(10):2157-9. PubMed ID: 21878428
[No Abstract] [Full Text] [Related]
28. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
Herbst RS; Hong WK
Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
[TBL] [Abstract][Full Text] [Related]
29. Cetuximab-induced hypertrichosis of the scalp and eyelashes.
Vano-Galvan S; Ríos-Buceta L; Ma DL; Fernández-Chacón C; Viera JC; Jaén P
J Am Acad Dermatol; 2010 Mar; 62(3):531-3. PubMed ID: 20159332
[No Abstract] [Full Text] [Related]
30. Integrating biologically targeted therapy in head and neck squamous cell carcinomas.
Le QT; Raben D
Semin Radiat Oncol; 2009 Jan; 19(1):53-62. PubMed ID: 19028346
[TBL] [Abstract][Full Text] [Related]
31. Trastuzumab (Herceptin)-associated lung injury.
Vahid B; Mehrotra A
Respirology; 2006 Sep; 11(5):655-8. PubMed ID: 16916343
[TBL] [Abstract][Full Text] [Related]
32. Cetuximab in squamous cell carcinoma of the head and neck.
Hitt R; Martín P; Hidalgo M
Future Oncol; 2006 Aug; 2(4):449-57. PubMed ID: 16922611
[TBL] [Abstract][Full Text] [Related]
33. Toxic epidermal necrolysis caused by cetuximab plus minocycline in head and neck cancer.
Lee SS; Chu PY
Am J Otolaryngol; 2010; 31(4):288-90. PubMed ID: 20015761
[TBL] [Abstract][Full Text] [Related]
34. Durable complete remission induced by cetuximab monotherapy in a patient infected with HIV and diagnosed with recurrent squamous cell carcinoma of the head and neck.
Rubinstein PG; Lindgren V; Setty S; Yao M; Pytynia KB; Radosevich JA; Kadkol SS; Feldman LE
J Clin Oncol; 2011 Mar; 29(9):e222-5. PubMed ID: 21189379
[No Abstract] [Full Text] [Related]
35. Abnormal hair growth in a patient with head and neck cancer treated with the anti-epidermal growth factor receptor monoclonal antibody cetuximab.
Montagut C; Grau JJ; Grimalt R; Codony J; Ferrando J; Albanell J
J Clin Oncol; 2005 Aug; 23(22):5273-5. PubMed ID: 16051981
[No Abstract] [Full Text] [Related]
36. Severe cutaneous toxicity during concomitant radiotherapy and cetuximab treatment of head and neck cancer.
Vano-Galvan S; de las Heras E; Harto A; Jaen P
Eur J Dermatol; 2008; 18(4):471-2. PubMed ID: 18573734
[No Abstract] [Full Text] [Related]
37. Expanding the Reach of Anti-PD-1 Therapy.
Cancer Discov; 2015 Jul; 5(7):684-5. PubMed ID: 26034052
[TBL] [Abstract][Full Text] [Related]
38. A retrospective, multicenter study of the tolerance of induction chemotherapy with docetaxel, Cisplatin, and 5-Fluorouracil followed by radiotherapy with concomitant cetuximab in 46 cases of squamous cell carcinoma of the head and neck.
Buiret G; Combe C; Favrel V; Pommier P; Martin L; Ecochard R; Fayette J; Tartas S; Ramade A; Céruse P
Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):430-7. PubMed ID: 19775831
[TBL] [Abstract][Full Text] [Related]
39. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.
Hoeben BA; Molkenboer-Kuenen JD; Oyen WJ; Peeters WJ; Kaanders JH; Bussink J; Boerman OC
Int J Cancer; 2011 Aug; 129(4):870-8. PubMed ID: 20957635
[TBL] [Abstract][Full Text] [Related]
40. Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?
Bernier J; Schneider D
Eur J Cancer; 2007 Jan; 43(1):35-45. PubMed ID: 17098420
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
